Composition for detecting esophageal cancer and use thereof
By using the target sequences of MT1A and EPO genes for methylation status detection in the esophageal cancer detection, the problems of inconvenience and low sensitivity of esophageal cancer detection in the prior art are solved, and rapid, convenient and efficient detection of esophageal cancer is achieved. It improves the detection rate of early esophageal cancer.
Patent Information
- Application Number
- CN202210026506.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2017-12-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2037-12-01
AI Technical Summary
The existing esophageal cancer detection technology has problems such as inconvenience, low sensitivity and high cost, especially in the detection and screening of early esophageal cancer, and lacks high sensitivity and high specificity of methylated gene markers.
Provided a composition for detecting esophageal cancer in vitro, including a nucleic acid for detecting the methylated state of a target gene, specifically a target sequence of the MT1A gene and EPO gene, combined with specific Primers, probes and blockers can achieve sensitive and specific detection of esophageal cancer.
It has achieved rapid, convenient and efficient detection of esophageal cancer, and can distinguish esophageal cancer from normal samples in non-invasive areas in vitro, improves the detection rate and detection sensitivity of early esophageal cancer, and has important clinical application value.
Smart Images

Figure HDA0003464917920000011 
Figure HDA0003464917920000021 
Figure HDA0003464917920000022
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201711248825.5, invention name “Composition for detecting esophageal cancer and its use” and application date December 1, 2017. Technical Field
[0002] The invention belongs to the field of biotechnology, and relates to a composition and its use in disease detection, and specifically to a composition for detecting esophageal cancer and its corresponding kit and use. Background Art
[0003] Esophageal cancer is a common digestive tract tumor. About 300,000 people die of esophageal cancer every year worldwide. China is one of the areas with a high incidence of esophageal cancer in the world. Half of the patients who died of esophageal cancer worldwide were from China. According to the data from the National Cancer Prevention and Treatment Office: In 2015, the incidence of esophageal cancer in my country was 478 cases per 100,000 people, and the mortality rate was 375 cases per 10,000 people, ranking fourth and third among common cancers in my country, respectively. The mortality rate of esophageal cancer is close to 80%, and it is a highly malignant cancer. An important factor leading to the high mortality rate of esophageal cancer is the low diagnosis rate of early esophageal cancer. The cure rate of early esophageal cancer is much higher than that of middle and late stages, but because early esophageal cancer lacks obvious and specific symptoms, most patients have already developed into the middle and late stages when diagnosed. Clinical studies have found that it takes an average of several years from the formation of cancer lesions to the onset of clinical symptoms in patients; this provides an effective window period for discovering early esophageal cancer and increasing the diagnosis rate of early esophageal cancer. Making full use of this window period is expected to improve the treatment effect of esophageal cancer and reduce the mortality rate of esophageal cancer.
[0004] Currently, the technologies used in clinical diagnosis of esophageal cancer have limited application in the detection and screening of early esophageal cancer, mainly because: 1) Tissue biopsy is highly invasive and not suitable for early cancer screening; 2) Imaging detection technologies (such as esophageal radiography and endoscopy) are limited in equipment cost, operating technology, and invasiveness, and are difficult to promote on a large scale as cancer screening technologies; 3) Traditional serum tumor markers (such as AFP, CEA, CA125, and CA199, etc.) have low sensitivity for esophageal cancer detection and cannot fully meet the requirements of early cancer screening.
[0005] Recent studies have shown that epigenetics plays an important role in the occurrence and development of cancer. As an important mechanism of epigenetics, DNA methylation regulation in various cancers has been studied in depth. Research data show that the regulation of gene methylation is related to biological mechanisms such as chromatin structure and gene expression regulation; changes in cellular gene methylation occur in the early stages of tumor formation and throughout the occurrence and development of cancer; methylation of tumor suppressor genes is an important molecular mechanism for the transformation of precancerous lesions into malignant tumor cells. However, there is currently a lack of detection technology, methods and products for methylation gene detection in esophageal cancer. Therefore, there is currently a demand for methylation gene markers with high sensitivity and specificity for esophageal cancer detection. Summary of the invention
[0006] Based on this, in view of the problems of inconvenient detection, low sensitivity, and high cost in the existing esophageal cancer detection technology, the present invention provides a composition for detecting esophageal cancer. The composition provided by the present invention can detect esophageal cancer sensitively and specifically. The present invention also provides a kit comprising the composition and its use in detecting esophageal cancer. The kit provided by the present invention has good sensitivity for detecting esophageal cancer and can detect esophageal cancer conveniently, quickly, and effectively.
[0007] The present invention provides a composition, a kit and uses thereof for in vitro detection of esophageal cancer, a method for performing detection based on the kit, and a method for detecting esophageal cancer.
[0008] Specifically, the present invention relates to the following:
[0009] 1. A composition for in vitro detection of esophageal cancer, comprising:
[0010] Nucleic acid used to detect the methylation status of the target gene,
[0011] Wherein, the target gene is one or both of the MT1A gene and the EPO gene.
[0012] 2. The composition according to item 1, wherein the target sequence of the MT1A gene is as shown in SEQ ID NO: 1.
[0013] 3. The composition according to item 1, wherein the target sequence of the EPO gene is as shown in SEQ ID NO: 3.
[0014] 4. The composition according to any one of items 1 to 3, wherein the nucleic acid for detecting the methylation status of the target gene comprises:
[0015] A fragment of at least 9 nucleotides in the target sequence of the target gene,
[0016] The fragment comprises at least one CpG dinucleotide sequence.
[0017] 5. The composition according to any one of items 1 to 4, wherein the nucleic acid for detecting the methylation status of the target gene includes:
[0018] A fragment of at least 15 nucleotides that hybridizes to the target sequence of the target gene under moderately stringent or stringent conditions,
[0019] The fragment comprises at least one CpG dinucleotide sequence.
[0020] 6. The composition according to any one of items 1 to 5, further comprising:
[0021] A reagent that converts unmethylated cytosine base at position 5 of the target gene sequence into uracil.
[0022] 7. The composition according to any one of items 1 to 6, wherein the nucleic acid for detecting the methylation status of the target gene further comprises:
[0023] Blockers that preferentially bind to target sequences in their unmethylated state.
[0024] 8. The composition according to item 7, wherein
[0025] The fragment of at least 9 nucleotides is a sequence of SEQ ID NO: 5 and SEQ ID NO: 6, or a sequence of SEQ ID NO: 9 and SEQ ID NO: 10,
[0026] The fragment of at least 15 nucleotides is the sequence of SEQ ID NO: 7 or the sequence of SEQ ID NO: 11,
[0027] The blocker is the sequence of SEQ ID NO:8 or the sequence of SEQ ID NO:12.
[0028] 9. An oligonucleotide for in vitro detection of esophageal cancer, comprising:
[0029] A fragment of at least 9 nucleotides in SEQ ID NO: 1 or its complementary sequence and comprising at least one CpG dinucleotide sequence; and / or
[0030] The fragment of SEQ ID NO: 3 or its complementary sequence has at least 9 nucleotides and contains at least one CpG dinucleotide sequence.
[0031] 10. The oligonucleotide according to item 9, further comprising:
[0032] A fragment that hybridizes to at least 15 nucleotides of SEQ ID NO: 1 or its complementary sequence under moderately stringent or stringent conditions and comprises at least one CpG dinucleotide sequence; and / or
[0033] A fragment that hybridizes to at least 15 nucleotides of SEQ ID NO: 3 or its complementary sequence under moderately stringent or stringent conditions and comprises at least one CpG dinucleotide sequence.
[0034] 11. The oligonucleotide according to item 10, further comprising:
[0035] Blockers that preferentially bind to target sequences in their unmethylated state.
[0036] 12. An oligonucleotide for in vitro detection of esophageal cancer, comprising:
[0037] Sequences of SEQ ID NO:5 and SEQ ID NO:6.
[0038] 13. The oligonucleotide according to item 12, further comprising:
[0039] Sequence of SEQ ID NO:7.
[0040] 14. The oligonucleotide according to item 13, further comprising:
[0041] Sequence of SEQ ID NO:8.
[0042] 15. An oligonucleotide for in vitro detection of esophageal cancer, comprising:
[0043] Sequences of SEQ ID NO:9 and SEQ ID NO:10.
[0044] 16. The oligonucleotide according to item 15, further comprising:
[0045] The sequence of SEQ ID NO:11.
[0046] 17. The oligonucleotide according to item 16, further comprising:
[0047] Sequence of SEQ ID NO:12.
[0048] 18. Use of MT1A gene in preparing a kit for in vitro detection of esophageal cancer.
[0049] 19. Use of EPO gene in preparing a kit for in vitro detection of esophageal cancer.
[0050] 20. A kit comprising the composition according to any one of items 1 to 8 or the oligonucleotide according to any one of items 9 to 17.
[0051] 21. The kit according to item 20, further comprising at least one other component selected from the group consisting of:
[0052] Nucleoside triphosphates, DNA polymerase and buffer required for the function of the DNA polymerase.
[0053] 22. The kit according to item 20 or 21, further comprising: instructions.
[0054] 23. Use of the composition according to any one of Items 1 to 8 or the oligonucleotide according to any one of Items 9 to 17 for preparing a kit for in vitro detection of esophageal cancer.
[0055] 24. The use according to any one of items 18, 19 and 23, wherein the kit for in vitro detection of esophageal cancer detects esophageal cancer by a method comprising the following steps:
[0056] 1) separating a DNA sample including a target gene target sequence or a fragment thereof from a biological sample to be tested;
[0057] 2) determining the methylation status of the target sequence of the target gene;
[0058] 3) The state of the biological sample is judged by the detection result of the methylation state of the target gene target sequence, thereby realizing in vitro detection of esophageal cancer.
[0059] 25. The use according to item 24, wherein the method comprises the steps of:
[0060] Extracting genomic DNA from the biological sample to be tested;
[0061] Treat the extracted genomic DNA with a reagent to convert the unmethylated cytosine base at position 5 into uracil or other bases;
[0062] contacting the reagent-treated DNA sample with a DNA polymerase and a primer of a target sequence of a target gene, and performing a DNA polymerization reaction in the presence of a blocking agent that preferentially binds to the target sequence in a non-methylated state;
[0063] detecting the amplified product with a probe; and
[0064] Based on the presence or absence of the amplification product, the methylation status of at least one CpG dinucleotide of the target sequence of the target gene is determined.
[0065] 26. The use according to item 25, wherein the reagent is a bisulfite reagent.
[0066] 27. A method for detecting esophageal cancer, comprising the following steps:
[0067] Separating a DNA sample including a target gene target sequence or a fragment thereof from a biological sample to be tested;
[0068] Determining the methylation status of the target gene target sequence; and
[0069] The state of the biological sample is judged by the detection result of the methylation state of the target gene target sequence, thereby realizing in vitro detection of esophageal cancer.
[0070] 28. A method for detecting esophageal cancer, comprising the following steps:
[0071] Extracting genomic DNA from the biological sample to be tested;
[0072] Treat the extracted genomic DNA with a reagent to convert the unmethylated cytosine base at position 5 into uracil or other bases;
[0073] contacting the reagent-treated DNA sample with a DNA polymerase and a primer of a target sequence of a target gene, and performing a DNA polymerization reaction in the presence of a blocking agent that preferentially binds to the target sequence in a non-methylated state;
[0074] detecting the amplified product with a probe; and
[0075] Based on the presence or absence of the amplification product, the methylation status of at least one CpG dinucleotide of the target sequence of the target gene is determined.
[0076] 29. The method according to item 27 or 28, wherein
[0077] The target gene is one or both of the MT1A gene and the EPO gene.
[0078] 30. The method according to item 29, wherein the target sequence of the MT1A gene is as shown in SEQ ID NO: 1.
[0079] 31. The method according to item 29, wherein the target sequence of the EPO gene is as shown in SEQ ID NO: 3.
[0080] 32. A method according to claim 28, wherein the reagent is a bisulfite reagent.
[0081] 33. The method according to item 28, wherein the primer is:
[0082] A fragment of at least 9 nucleotides in SEQ ID NO: 1 or its complementary sequence and comprising at least one CpG dinucleotide sequence; and / or
[0083] The fragment of SEQ ID NO: 3 or its complementary sequence has at least 9 nucleotides and contains at least one CpG dinucleotide sequence.
[0084] 33. A method according to claim 28, wherein the blocker is a blocker that preferentially binds to a target sequence in an unmethylated state.
[0085] 34. The method according to item 28, wherein the probe is:
[0086] A fragment that hybridizes to at least 15 nucleotides of SEQ ID NO: 1 or its complementary sequence under moderately stringent or stringent conditions and comprises at least one CpG dinucleotide sequence; and / or
[0087] A fragment that hybridizes to at least 15 nucleotides of SEQ ID NO: 3 or its complementary sequence under moderately stringent or stringent conditions and comprises at least one CpG dinucleotide sequence.
[0088] 35. The method according to item 33, wherein the primers are sequences of SEQ ID NO:5 and SEQ ID NO:6, or they are sequences of SEQ ID NO:9 and SEQ ID NO:10.
[0089] 36. The method according to item 33, wherein the blocking agent is the sequence of SEQ ID NO: 8 or the sequence of SEQ ID NO: 12
[0090] 37. The method according to item 34, wherein the probe is the sequence of SEQ ID NO:7 or the sequence of SEQ ID NO:11.
[0091] The inventors of the present invention used epigenomics and bioinformatics techniques to analyze the whole genome methylation data of esophageal cancer tissues and adjacent control tissues, and found two methylated genes related to esophageal cancer, and determined the target sequences of these two esophageal cancer methylated genes with abnormal methylation; further, the inventors of the present invention found that the target sequences of these two esophageal cancer methylated genes can be used to sensitively and specifically detect the methylation status of these two genes, so that they can be used to detect peripheral blood free DNA. The detection of peripheral blood samples of esophageal cancer patients and normal control individuals showed that the composition and detection method described in the present invention can sensitively and specifically detect esophageal cancer, including two common esophageal cancers of different cell types: squamous cell carcinoma and adenocarcinoma. Therefore, the present invention provides a composition and detection method that can be used for in vitro detection of esophageal cancer, which has important clinical application value.
[0092] Other features and advantages of the present invention will be described in detail by the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0093] The above and other features of the present invention will be further described below in conjunction with the accompanying drawings and detailed description thereof. It should be understood that these drawings only illustrate several exemplary embodiments according to the present invention and therefore should not be regarded as limiting the scope of protection of the present invention. Unless otherwise specified, the accompanying drawings are not necessarily to scale and similar reference numerals represent similar components.
[0094] Figure 1 A diagram showing the results of screening the target gene of the present invention.
[0095] Figure 2 The composition and detection method provided by the present invention are used to detect leukocyte genomic DNA (negative reference for the methylation state of the target gene target sequence) and leukocyte genomic DNA treated with DNA methyltransferase (positive reference for the methylation state of the target gene target sequence). The results show that the composition and detection method provided by the present invention detect negative results for leukocyte genomic DNA, and positive results for leukocyte genomic DNA treated with DNA methyltransferase.
[0096] Figure 3 The present invention provides a result diagram of in vitro non-invasive detection of esophageal cancer by utilizing the composition and detection method and detecting the methylation status of the target gene target sequence. DETAILED DESCRIPTION
[0097] On the one hand, the present invention provides a composition for in vitro detection of esophageal cancer, the composition comprising a nucleic acid for detecting the methylation status within a target sequence of a target gene, wherein the target gene is one or both of the MT1A gene and the EPO gene.
[0098] The present invention provides a group of target gene target sequences that are abnormally methylated in esophageal cancer, including target sequences of the MT1A gene and the EPO gene. The target sequence of the MT1A gene is shown in SEQ ID NO: 1-2, and the target sequence of the EPO gene is shown in SEQ ID NO: 3-4.
[0099] The target sequence of the MT1A gene is shown in SEQ ID NO:1.
[0100] SEQ ID NO:1
[0101] CACCCAGGGGAGCTCAGTGGACTGTGCGCCTTGCCTTTCTGCTGCGCAAAGCCCAGTCCAGGTCATCACCTCGGGCGGGGCGGACTCGGCTGGGCGGACTCAGCGGGGCGGGCGCAGGCGCAGGGCGGGTCCTTTGCGTCCGGCCCTCTTTCCCCTGACCATAAAAGCAGC
[0102] The complementary sequence of SEQ ID NO: 1 is shown in SEQ ID NO: 2.
[0103] SEQ ID NO:2
[0104] GCTGCTTTTATGGTCAGGGGAAAGAGGGCCGGACGCAAAGGACCCGCCCTGCGCCTGCGCCCGCCCCGCTGAGTCCGCCCAGCCGAGTCCGCCCCGCCCGAGGTGATGACCTGGACTGGGCTTTGCGCAGCAGAAAGGCAAGGCGCACAGTCCACTGAGCTCCCCTGGGTG
[0105] Preferably, the sequence of the target sequence of the EPO gene is shown in SEQ ID NO: 3.
[0106] SEQ ID NO:3
[0107] CGCGCACGCACACATGCAGATAACAGCCCCGACCCCCGGCCAGAGCCGCAGAGTCCCTGGGCCACCCCGGCCGCTCGCTGCGCTGCGCCGCACCGCGCTGTCCTCCCGGAGCCGGACCGGGGCCACCGCGCCCGCTCTGCTCCGACACCGCGCCCCCTGGACAGCCGCCCTCTCCTCCAGGCCCGTGGGGCTGGCCCTGCACCGCCGAGCTTCCCGGGATGAGGGCCCCCGGTGTGGTCACCCGGCGCGCCCCAGGTCG
[0108] The complementary sequence of SEQ ID NO: 3 is shown in SEQ ID NO: 4.
[0109] CGACCTGGGGCGCGCCGGGTGACCACACCGGGGGCCCTCATCCCGGGAAGCTCGGCGGTGCAGGGCCAGCCCCACGGGCCTGGAGGAGAGGGCGGCTGTCCAGGGGGCGCGGTGTCGGAGCAGAGCGGG CGCGGTGGCCCCGGTCCGGCTCCGGGAGGACAGCGCGGTGCGGCGCAGCGCAGCGAGCGGCCGGGGGTGGCCCAGGGACTCTGCGGCTCTGGCCGGGGGTCGGGGCTGTTATCTGCATGTGTGCGTGCGCG
[0110] Preferably, the nucleic acid used to detect the methylation status of the target gene includes a fragment of at least 9 nucleotides in the target gene target sequence, wherein the fragment contains at least one CpG dinucleotide sequence. In certain preferred embodiments, if the test sample DNA is converted using bisulfite, the nucleic acid used to detect the methylation status of the target gene includes a fragment of at least 9 nucleotides in the sequence after the target gene target sequence is converted with bisulfite, wherein the nucleotide fragment contains at least one CpG dinucleotide sequence.
[0111] More preferably, the nucleic acid used to detect the methylation status of the target gene includes a fragment of at least 15 nucleotides that hybridizes to the target gene target sequence under moderate stringency or stringent conditions, wherein the nucleotide fragment contains at least one CpG dinucleotide sequence. In certain preferred embodiments, if the test sample DNA is converted using bisulfite, the nucleic acid used to detect the methylation status of the target gene includes a fragment of at least 15 nucleotides in the sequence of the target gene target sequence after bisulfite conversion under moderate stringency or stringent conditions, wherein the nucleotide fragment contains at least one CpG dinucleotide sequence.
[0112] Preferably, the composition further comprises a reagent for converting the unmethylated cytosine base at position 5 of the target gene target sequence into uracil. More preferably, the reagent is bisulfite.
[0113] Preferably, the nucleic acid used to detect the methylation status of the target gene also includes a blocker that preferentially binds to DNA in a non-methylated state.
[0114] Preferably, the composition comprises one or more of the following primers, probes and / or blockers:
[0115] MT1A Primer F
[0116] SEQ ID NO:5
[0117] CGGACGTAAAGGATTC
[0118] MT1A Primer R
[0119] SEQ ID NO:6
[0120] GAAACGAACTCGACTAAACG
[0121] MT1A probe
[0122] SEQ ID NO:7
[0123] TGCGTTTGCGTTCGTTTCG
[0124] MT1A blockers
[0125] SEQ ID NO:8
[0126] CAAACTCAACTAAACAAACTCAACAAAACAAAC
[0127] EPO Primer F
[0128] SEQ ID NO:9
[0129] AGTCGTAGAGTTTTTGGGTT
[0130] EPO Primer R
[0131] SEQ ID NO:10
[0132] CAACGCGATACGACG
[0133] EPO probe
[0134] SEQ ID NO:11
[0135] CGCAACGAACGACCGA
[0136] EPO blockers
[0137] SEQ ID NO:12
[0138] GAGTTTTTGGGTTATTTTGGTTGTTTGTTG
[0139] On the other hand, the present invention provides an oligonucleotide for in vitro detection of esophageal cancer, comprising: a fragment of at least 9 nucleotides in SEQ ID NO:1 or its complementary sequence and containing at least one CpG dinucleotide sequence; and / or a fragment of at least 9 nucleotides in SEQ ID NO:3 or its complementary sequence and containing at least one CpG dinucleotide sequence.
[0140] Preferably, the oligonucleotide for in vitro detection of esophageal cancer comprises: a fragment of at least 9 nucleotides in a sequence after bisulfite conversion of SEQ ID NO: 1 or its complementary sequence; and / or a fragment of at least 9 nucleotides in a sequence after bisulfite conversion of SEQ ID NO: 3 or its complementary sequence and containing at least one CpG dinucleotide sequence.
[0141] The oligonucleotides for in vitro detection of esophageal cancer of the present invention further include: a fragment that hybridizes to at least 15 nucleotides in the SEQ ID NO:1 or its complementary sequence under moderately stringent or stringent conditions and contains at least one CpG dinucleotide sequence; and / or a fragment that hybridizes to at least 15 nucleotides in the SEQ ID NO:3 or its complementary sequence under moderately stringent or stringent conditions and contains at least one CpG dinucleotide sequence.
[0142] Preferably, the oligonucleotide for in vitro detection of esophageal cancer comprises: a fragment of at least 15 nucleotides in a sequence after bisulfite conversion of SEQ ID NO: 1 or its complementary sequence that hybridizes under moderately stringent or stringent conditions and contains at least one CpG dinucleotide sequence; and / or a fragment of at least 15 nucleotides in a sequence after bisulfite conversion of SEQ ID NO: 3 or its complementary sequence that hybridizes under moderately stringent or stringent conditions and contains at least one CpG dinucleotide sequence.
[0143] The oligonucleotide for in vitro detection of esophageal cancer of the present invention further comprises: a blocker that preferentially binds to DNA in a non-methylated state.
[0144] In a specific embodiment, the oligonucleotide for in vitro detection of esophageal cancer includes: sequences of SEQ ID NO: 5 and SEQ ID NO: 6. It also includes: sequence of SEQ ID NO: 7. It also includes: sequence of SEQ ID NO: 8.
[0145] In another specific embodiment, the oligonucleotide for in vitro detection of esophageal cancer includes: sequences of SEQ ID NO: 9 and SEQ ID NO: 10. It also includes: sequence of SEQ ID NO: 11. It also includes: sequence of SEQ ID NO: 12.
[0146] In another aspect, the present invention provides a kit comprising the composition, which further comprises at least one other component selected from the group consisting of nucleoside triphosphates, DNA polymerase, and a buffer required for the function of the DNA polymerase.
[0147] The present invention also relates to the use of MT1A gene and / or EPO gene in preparing a kit for in vitro detection of esophageal cancer.
[0148] Among them, the MT1A is metallothionein 1A, which is located in the q13 region of human chromosome 16 and belongs to the metallothionein gene family. Metallothionein is a small molecule protein rich in cysteine, lacks aromatic amino acids, and can bind divalent heavy metal ions. Metallothionein is an antioxidant that can protect cells from damage by free radicals containing hydroxyl groups, maintain the balance of metal ions in cells, and play a role in removing the toxicity of heavy ions. The loss of metallothionein gene function can lead to pathological phenomena such as the occurrence of cancer.
[0149] The EPO gene is the erythropoietin gene, which is located in the q22.1 region of human chromosome 7. The protein encoded by the gene is a glycosylated cytokine secreted by cells. When erythropoietin binds to the corresponding receptor, it can promote the synthesis of red blood cells.
[0150] In another aspect, the present invention provides a method for detecting esophageal cancer in vitro, the method comprising the following steps:
[0151] 1) Separating the target gene sequence or fragment thereof in the biological sample to be tested;
[0152] 2) determining the methylation status of the target sequence of the target gene;
[0153] 3) The state of the biological sample is judged by the detection result of the methylation state of the target gene target sequence, thereby realizing in vitro detection of esophageal cancer.
[0154] According to certain preferred embodiments, the method further comprises the following steps:
[0155] 1) Extracting genomic DNA from the biological sample to be tested;
[0156] 2) treating the DNA sample obtained in step 1) with a reagent to convert the unmethylated cytosine base at position 5 into uracil or other bases, that is, the unmethylated cytosine base at position 5 of the target gene target sequence is converted into uracil or other bases, and the converted base is different from the unmethylated cytosine base at position 5 in terms of hybridization performance and is detectable;
[0157] 3) contacting the DNA sample treated in step 2) with a DNA polymerase and a primer of the target gene target sequence, so that the treated target gene target sequence is amplified to produce an amplification product or is not amplified; if the treated target gene target sequence undergoes a DNA polymerization reaction, an amplification product will be produced; if the treated target gene target sequence does not undergo a DNA polymerization reaction, it will not be amplified;
[0158] 4) detecting the amplified product with a probe; and
[0159] 5) Determining the methylation status of at least one CpG dinucleotide of the target sequence of the target gene based on the presence or absence of the amplification product.
[0160] Preferably, a typical primer includes a fragment of the target gene target sequence, which contains a fragment of at least 9 nucleotides that are identical, complementary, or hybridize under moderately stringent or stringent conditions to SEQ ID NO: 1-2 and SEQ ID NO: 3-4.
[0161] Preferably, a typical probe is a fragment of the target gene target sequence, and the fragment of the target gene target sequence comprises a fragment of at least 15 nucleotides selected from SEQ ID NO: 1-2 and SEQ ID NO: 3-4 that is identical, complementary or hybridizes under moderately stringent or stringent conditions.
[0162] Preferably, the typical blocker is one that preferentially binds to DNA in an unmethylated state.
[0163] Preferably, one or more of the primers, probes and / or blockers are as follows:
[0164] MT1A Primer F
[0165] SEQ ID NO:5
[0166] CGGACGTAAAGGATTC
[0167] MT1A Primer R
[0168] SEQ ID NO:6
[0169] GAAACGAACTCGACTAAACG
[0170] MT1A probe
[0171] SEQ ID NO:7
[0172] TGCGTTTGCGTTCGTTTCG
[0173] MT1A blockers
[0174] SEQ ID NO:8
[0175] CAAACTCAACTAAACAAACTCAACAAAACAAAC
[0176] EPO Primer F
[0177] SEQ ID NO:9
[0178] AGTCGTAGAGTTTTTGGGTT
[0179] EPO Primer R
[0180] SEQ ID NO:10
[0181] CAACGCGATACGACG
[0182] EPO probe
[0183] SEQ ID NO:11
[0184] CGCAACGAACGACCGA
[0185] EPO blockers
[0186] SEQ ID NO:12
[0187] GAGTTTTTGGGTTATTTTGGTTGTTTGTTG
[0188] Furthermore, the contacting or amplifying comprises using at least one of the following methods: using a thermostable DNA polymerase as the amplification enzyme, using a polymerase lacking 5-3' exonuclease activity, using polymerase chain reaction (PCR), and generating amplification product nucleic acid molecules with detectable labels.
[0189] According to certain preferred embodiments, the methylation state of at least one CpG dinucleotide in the target gene target sequence is determined by the cycle threshold Ct value of the PCR reaction. By using the method of analyzing DNA in a biological sample by PCR reaction, the methylation state of the target gene target sequence can be conveniently detected, and whether the sample is positive can be quickly and conveniently determined based on the cycle threshold of the PCR reaction, thereby providing a non-invasive and rapid in vitro detection method for esophageal cancer.
[0190] The biological sample is selected from the group consisting of cell lines, histological sections, tissue biopsy / paraffin-embedded tissue, body fluids, feces, colon effluent, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, or a combination thereof.
[0191] A preferred biological sample is plasma.
[0192] The present invention also provides a kit comprising the composition. Typically, the kit comprises a container for containing a patient's biological sample. Furthermore, the kit also comprises instructions for use and interpretation of the test results.
[0193] The present invention provides a method for in vitro non-invasive detection of esophageal cancer by detecting the methylation state of target gene target sequences. The inventors found that there was a significant difference between the methylation state of the MT1A gene and the EPO gene target sequences in esophageal cancer tissue and the methylation state of the gene target sequences in normal esophageal tissue: in esophageal cancer tissue, the MT1A gene and the EPO gene target sequences were methylated, while in normal esophageal tissue, the MT1A gene and the EPO gene target sequences were not methylated. Therefore, the present application provides a method for in vitro detection of esophageal cancer by detecting the methylation state of the MT1A gene and the EPO gene target sequences in a sample. The method provided by the present invention can detect esophageal cancer non-invasively and quickly.
[0194] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those commonly understood by those skilled in the art. Although similar or identical methods and materials as those described herein can be used in experiments or practical applications, the materials and methods are described herein below. In the event of a conflict, the present specification, including definitions, shall prevail. In addition, the materials, methods and examples are provided for illustration only and are not intended to be limiting.
[0195] The present invention also provides a composition capable of sensitively and specifically detecting the methylation state of a target gene target sequence; and a method and a kit for in vitro non-invasive detection of esophageal cancer.
[0196] The following descriptions are examples of the compositions, kits, nucleic acid sequences, and detection methods of the present invention. The first group of embodiments discloses a target gene and a target gene target sequence; the second group of embodiments discloses a composition for detecting the methylation state of a target gene target sequence, including a nucleic acid for detecting the methylation state of a target gene target sequence; the third group of embodiments discloses a method for in vitro non-invasive detection of esophageal cancer by detecting the methylation state of a target gene target sequence.
[0197] In certain embodiments, the composition further comprises an agent for converting the unmethylated cytosine base at position 5 of the gene into uracil. Preferably, the agent is bisulfite. Bisulfite modification of DNA is a known tool for assessing the methylation status of CpGs. In the DNA of eukaryotic cells, 5-methylcytosine is the most common covalent base modification. 5-methylcytosine cannot be identified by sequencing because 5-methylcytosine has the same base pairing behavior as cytosine. In addition, during PCR amplification, the epigenetic information carried by 5-methylcytosine is completely lost. The method most commonly used to analyze the presence of 5-methylcytosine in DNA is based on the specific reaction of bisulfite with cytosine; after subsequent alkaline hydrolysis, unmethylated cytosine is converted into uracil, which corresponds to thymine in pairing behavior; but under these conditions, 5-methylcytosine remains unmodified. Thus the original DNA is transformed in this way so that the 5-methylcytosine, which was originally indistinguishable from cytosine in its hybridization behavior, can now be detected as the only remaining cytosine by conventional known molecular biology techniques, such as by amplification and hybridization. All of these techniques are based on different base pairing properties and can now be fully utilized. Therefore, typically, the present application provides the combined use of bisulfite technology and one or more methylation assays to determine the methylation state of the CpG dinucleotide sequence in the target gene target sequence. In addition, the method of the present invention is suitable for analyzing heterogeneous biological samples, such as low-concentration tumor cells in blood or feces. Therefore, when analyzing the methylation state of the CpG dinucleotide sequence in such a sample, those skilled in the art can use quantitative determination methods to determine the methylation level (such as percentage, number, ratio, proportion or degree) of a specific CpG dinucleotide sequence, rather than the methylation state. Accordingly, the term methylation status or methylation state should also be considered to refer to the value reflecting the methylation state of the CpG dinucleotide sequence.
[0198] In certain embodiments, the method of the present application specifically includes: 1) extracting genomic DNA of a biological sample to be tested; 2) using a reagent to treat the DNA sample obtained in step 1) to convert the unmethylated cytosine base at position 5 into uracil or other bases, that is, the unmethylated cytosine base at position 5 of the target gene target sequence is converted into uracil or other bases, and the converted base is different from the unmethylated cytosine base at position 5 in terms of hybridization performance and is detectable; 3) contacting the DNA sample treated in step 2) with a DNA polymerase and a primer of the target gene target sequence, so that the treated target gene target sequence is amplified to produce an amplification product or is not amplified; if the treated target gene target sequence undergoes a DNA polymerization reaction, an amplification product will be produced; if the treated target gene target sequence does not undergo a DNA polymerization reaction, it will not be amplified; 4) detecting the amplification product with a probe; 5) and determining the methylation state of at least one CpG dinucleotide of the target gene target sequence based on whether the amplification product exists.
[0199] Typically, the contacting or amplification includes using at least one of the following methods: using a thermostable DNA polymerase as the amplification enzyme; using a polymerase lacking 5-3' exonuclease activity; using PCR; producing an amplified product nucleic acid molecule with a detectable label. Preferably, the methylation status is determined by PCR, and assays such as "fluorescence-based real-time PCR technology", methylation-sensitive single nucleotide primer extension reaction (Ms-SNuPE), methylation-specific PCR (MSP), and methylated CpG island amplification (MCA) are used to determine the methylation status of at least one CpG dinucleotide of the target gene target sequence. Among them, the "fluorescence-based real-time PCR" assay is a high-throughput quantitative methylation assay that uses fluorescence-based real-time PCR (TaqMan) technology and does not require further operations after the PCR step. In short, the "fluorescence-based real-time PCR" method starts with a mixed sample of genomic DNA, which is converted into a mixed pool of methylation-dependent sequence differences in a sodium bisulfite reaction according to standard operations. Fluorescence-based PCR is then performed in a "biased" reaction (using PCR primers that overlap known CpG dinucleotides). Sequence differences can be generated at the amplification level and at the fluorescence detection amplification level. "Real-time PCR based on fluorescence" can be used as a quantitative test for methylation status in genomic DNA samples, where sequence differentiation occurs at the probe hybridization level. In this quantitative manner, in the presence of a fluorescent probe that overlaps a specific CpG dinucleotide, the PCR reaction provides methylation-specific amplification. The non-biased control for the amount of starting DNA is provided by the following reaction: neither the primer nor the probe covers any CpG dinucleotide. The "real-time PCR based on fluorescence" method can be used with any suitable probe, such as "TaqMan", "Lightcycler", etc. The TaqMan probe is a fluorescent reporter (Reporter) and a quencher molecule (Quencher) double-labeled, and is designed to be specific to a relatively high GC content region, so that it melts at a temperature of about 10°C higher than the forward or reverse primer in the PCR cycle. This allows the TaqMan probe to remain fully hybridized in the PCR annealing / extension step. When Taq polymerase synthesizes a new strand in PCR, it will eventually encounter the annealed TaqMan probe. The 5 to 3' endonuclease activity of Taq polymerase will then displace the TaqMan probe by digesting it, thereby releasing the fluorescent reporter molecule for quantitative detection of its now unquenched signal using a real-time fluorescence detection system. Typical reagents for "fluorescence-based real-time PCR" analysis can include, but are not limited to: PCR primers for the target gene target sequence; non-specific amplification blockers; TaqMan or Lightcycler probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase, etc.
[0200] Example
[0201] Example 1
[0202] By analyzing the whole genome methylation chip data of 233 cases of esophageal cancer tissues and 171 cases of normal esophageal tissues (HumanMethylation450k chip of Illumina), the inventors found that the methylation levels of MT1A gene and EPO gene in esophageal cancer tissues were significantly higher than those in normal esophageal tissues (analysis results are shown in Figure 2). Figure 1 ). Further, the inventors analyzed the probe sequences and corresponding methylation rate data of the MT1A gene and the EPO gene on the whole genome methylation chip, and found the sequence fragments with the most obvious methylation differences between the two target genes in esophageal cancer tissue and normal esophageal tissue, thereby determining them as the target sequences of the two target genes. The target sequence of the MT1A gene is shown in SEQ ID NO: 1. The complementary sequence of the target sequence of the MT1A gene is shown in SEQ ID NO: 2. The target sequence of the EPO gene is shown in SEQ ID NO: 3. The complementary sequence of the target sequence of the EPO gene is shown in SEQ ID NO: 4.
[0203] Example 2
[0204] The first step: obtain the DNA of the biological sample to be analyzed. The source can be any suitable source, such as cell lines, histological sections, biopsies, paraffin-embedded tissues, body fluids, feces, urine, plasma, serum, whole blood, separated blood cells, cells separated from blood, and all possible combinations thereof. Then separate by any standard means in the prior art, and separate DNA from the sample. In short, when DNA is wrapped in a cell membrane, the biological sample must be broken and cracked by enzyme, chemical or mechanical means. Subsequently, for example, protein and other contaminants are removed by digestion with protein kinase K. Then recover DNA from the solution. This can be achieved by various methods, including salting out, organic extraction, or binding DNA to a solid support. The choice of method can be affected by a variety of factors, including time, cost, and the amount of DNA required. When the sample DNA is not wrapped in a cell membrane (e.g., circulating DNA from a blood sample), standard methods for separating and / or purifying DNA in the prior art can be used. These methods include the use of protein degradation agents, such as chaotropic salts, such as guanidine hydrochloride or urea; or detergents, such as sodium dodecyl sulfate (SDS), cyanogen bromide. Other methods include, but are not limited to, ethanol precipitation or propanol precipitation, vacuum concentration by centrifugation, etc. Those skilled in the art can also use devices, such as filters such as ultrafiltration, silicon surfaces or membranes, magnetic particles, polystyrene particles, polystyrene surfaces, positively charged surfaces and positively charged membranes, charged membranes, charged surfaces, charged conversion membranes, charged conversion surfaces. Once the nucleic acid is extracted, the DNA is used for analysis.
[0205] In this embodiment, the biological sample DNA is leukocyte genomic DNA and leukocyte genomic DNA treated with DNA methyltransferase. The target gene target sequence of the leukocyte genomic DNA is in a non-methylated state, so the leukocyte genomic DNA is a negative reference for the methylation state of the target gene target sequence. The target gene target sequence of the leukocyte genomic DNA treated with DNA methyltransferase is in a methylated state, so the leukocyte genomic DNA treated with DNA methyltransferase is a positive reference for the methylation state of the target gene target sequence.
[0206] Step 2: The two DNA samples are treated separately so that the unmethylated cytosine base at position 5 is converted into uracil, thymine or another base that is not used for cytosine in hybridization behavior. Preferably, it is achieved by treatment with a bisulfite reagent. The term "bisulfite reagent" refers to a reagent comprising bisulfite, acid sulfite or a combination thereof, which can be used to distinguish methylated and unmethylated CpG dinucleotide sequences as disclosed herein. Preferably, the bisulfite treatment is carried out in the presence of a denaturing solvent, such as but not limited to n-alkyl glycol, especially diethylene glycol dimethyl ether (DME), or in the presence of dioxane or a dioxane derivative. In a preferred embodiment, the denaturing solvent is used at a concentration of 1% to 35% (v / v). It is also preferred that the bisulfite reaction is carried out in the presence of a scavenger, such as but not limited to a chromane derivative, such as 6-hydroxy-2,5,7,8,-tetramethylchromane 2-carboxylic acid or trihydroxybenzoic acid and its derivatives, such as gallic acid. The bisulfite conversion is preferably carried out at a reaction temperature of 30°C to 70°C, wherein the temperature is briefly increased to over 85°C during the reaction. The bisulfite-treated DNA is preferably purified prior to quantification. This can be carried out by any method known in the art, such as, but not limited to, ultrafiltration.
[0207] Step 3: Amplify the treated DNA fragments using the primers and amplification enzymes of the present invention. Several DNA fragments can be amplified simultaneously in the same reaction vessel. Preferably, the length of the amplified product is 100 to 2,000 base pairs. When the genomic DNA of the biological sample to be detected is a mixture of methylated and unmethylated states, especially when the DNA in the methylated state is far less than the DNA in the unmethylated state, such as free DNA in the peripheral blood of cancer patients, in order to improve the amplification specificity of the PCR amplification primers, the present invention uses a target gene target sequence-specific blocker in the PCR reaction system. The 5' end of the blocker nucleotide sequence has an overlap region of greater than or equal to 5 nucleotides with the 3' end nucleotide sequence of the forward (F) or reverse (R) primer; the blocker and the forward (F) or reverse (R) primer are complementary to the same strand of the target gene target sequence DNA; the melting temperature of the blocker is higher than that of the forward (F) or reverse (R) primer by more than (including) 5°C; the nucleotide sequence of the blocker contains at least one CpG dinucleotide sequence and is complementary to the sequence of the target gene target sequence DNA that has not been methylated after bisulfite conversion. Therefore, when the genomic DNA of the biological sample to be detected is a mixture of methylated and unmethylated states, especially when the DNA in the methylated state is far less than the DNA in the unmethylated state, the DNA in the unmethylated state will preferentially bind to the blocker after bisulfite conversion, thereby inhibiting the binding of the DNA template to the PCR primer, so that PCR amplification does not occur, while the DNA in the methylated state does not bind to the blocker, and thus binds to the primer, and PCR amplification occurs. Afterwards, the fragments obtained by amplification are directly or indirectly detected. Preferably the label is in the form of a fluorescent marker, a radionuclide or an attachable molecular fragment.
[0208] According to the target gene target sequences SEQ ID NO: 1-2 and SEQ ID NO: 3-4, the present invention designs primers, probes and blocker sequences (SEQ ID NO: 5-12) for detecting the methylation status of the two target gene target sequences MT1A and EPO:
[0209] Preferably, one or more of the primers, probes and / or blockers are as follows:
[0210] MT1A Primer F
[0211] SEQ ID NO:5
[0212] CGGACGTAAAGGATTC
[0213] MT1A Primer R
[0214] SEQ ID NO:6
[0215] GAAACGAACTCGACTAAACG
[0216] MT1A probe
[0217] SEQ ID NO:7
[0218] TGCGTTTGCGTTCGTTTCG
[0219] MT1A blockers
[0220] SEQ ID NO:8
[0221] CAAACTCAACTAAACAAACTCAACAAAACAAAC
[0222] EPO Primer F
[0223] SEQ ID NO:9
[0224] AGTCGTAGAGTTTTTGGGTT
[0225] EPO Primer R
[0226] SEQ ID NO:10
[0227] CAACGCGATACGACG
[0228] EPO probe
[0229] SEQ ID NO:11
[0230] CGCAACGAACGACCGA
[0231] EPO blockers
[0232] SEQ ID NO:12
[0233] GAGTTTTTGGGTTATTTTGGTTGTTTGTTG
[0234] In the present invention, various commercial real-time PCR instruments and equipment can be used to perform real-time PCR detection according to the standard operation of the prior art. According to certain specific embodiments, real-time PCR detection is performed on Life Technologies instruments (7500Fast). The PCR reaction mixture is composed of 25-40ng of DNA template converted by bisulfite and 300-600nM primers and blockers, 150-300nM probe, 1UTaq polymerase, 50-400μM of each dNTP, 1 to 10mM MgCl2 and 2XPCR buffer to a final volume of 2μl to 100μl. Continue for 3-60 minutes at 85 to 99°C to amplify the sample with pre-cycle, followed by annealing of 35-55 cycles of 1 to 30 seconds at 50 to 72°C, annealing and extension at 45 to 80°C for 5 to 90 seconds, and denaturation at 85 to 99°C for 5 to 90 seconds. By observing amplification only on the methylated target gene target sequence, the gene fragment is detected with a probe specific to the CpG island region of the target gene target sequence containing 5-methylcytosine. In addition, in some specific embodiments, the β-actin gene (ACTB) can be used as an internal reference for PCR, and the β-actin gene amplicon is created by using primers complementary to the β-actin gene sequence, and the β-actin gene amplicon is detected with a specific probe. Each sample is subjected to at least one real-time PCR, and in some specific embodiments, two or three real-time PCR tests are performed.
[0235] The experimental results show that Figure 2 The following: When the composition and detection method provided by the present invention are used to detect the leukocyte genomic DNA (negative reference for the methylation status of the target gene target sequence), no PCR amplification occurs, and the detection result is negative, that is, the target gene target sequence of the tested DNA sample is not methylated; When the composition and detection method provided by the present invention are used to detect the leukocyte genomic DNA (positive reference for the methylation status of the target gene target sequence) after DNA methyltransferase treatment, PCR amplification occurs, and the detection result is positive, that is, the target gene target sequence of the tested DNA sample is methylated. It can be judged that the composition and detection method provided by the present invention can specifically detect the methylation status of the target gene target sequence.
[0236] Example 3
[0237] According to a specific embodiment of the present application, based on the average Ct value of the test results of a certain number of esophageal cancer samples and normal samples, the Ct value of the target gene that can effectively distinguish esophageal cancer from normal is determined, that is, the critical value. The methylation state of at least one CpG dinucleotide of the target gene target sequence is determined by the cycle threshold Ct value of the polymerase chain reaction. By comparing the Ct value of the sample tested with the pre-set critical value, it is determined whether the analysis result based on the target gene is negative (normal) or positive (esophageal cancer).
[0238] This embodiment includes the following steps:
[0239] First, plasma samples from 20 patients with esophageal cancer and 22 normal subjects were obtained. All samples were from Boercheng Co., Ltd. Then, peripheral blood free DNA of the tested samples was extracted, and the DNA samples were pretreated so that the unmethylated cytosine base at position 5 was converted into uracil, thymine or another base that is not used for cytosine in hybridization behavior. In this embodiment, the pretreatment was achieved by treatment with a bisulfite reagent. The extraction and treatment of the DNA can be carried out by any standard means in the prior art. Specifically, in this embodiment, all sample DNA extraction and bisulfite DNA modification were extracted by using Boercheng Co., Ltd.'s plasma treatment kit.
[0240] Then, the above-mentioned target gene primer, probe and blocker combination were added to the DNA samples of the 20 esophageal cancer patients and 22 normal people treated above, and the methylation status of the target gene target sequence was detected by PCR. Among them, the PCR taken in this experimental example was carried out on a Life Technologies instrument (7500). The PCR reaction mixture consisted of 35ng of bisulfite-converted DNA template, 450nM primers and blockers, 225nM probes, 1UTaq polymerase, 200μM of each dNTP, 4.5mM MgCl2 and 2XPCR buffer to a final volume of 50μl. The sample was amplified with a pre-cycle at 94°C for 20 minutes, followed by 45 cycles of annealing at 62°C for 5 seconds, annealing and extension at 55.5°C for 35 seconds, and denaturation at 93°C for 30 seconds.
[0241] Finally, the Ct values of the real-time PCR of the target gene target sequence were measured for DNA samples from 20 esophageal cancer patients and 22 normal subjects. Figure 3As shown in the figure: 1) a specific critical value is selected, preferably the critical value Ct=37, and the methylation state of the target gene target sequence is detected by using the composition and the detection method provided by the present invention, which can effectively detect esophageal cancer patients; in this embodiment, when the Ct value of 37 is used as the critical value, the sensitivity of the target gene target sequence methylation to detect esophageal cancer is 55% (MT1A) and 45% (EPO), respectively; 2) the methylation of the target gene target sequence has good specificity, and the detection of normal people shows that the specificity of the target gene target sequence methylation to normal people is 95% (MT1A) and 95% (EPO); 3) by combining the methylation detection results of the MT1A gene and the EPO gene, the sensitivity of detecting esophageal cancer can be increased to 60%, while the specificity is not convenient, which is still 95%.
[0242] The above experimental results show that the methylated DNA of the target gene target sequence is a marker for esophageal cancer. Through the detection of methylated DNA of the target gene target sequence of the present invention, in vitro non-invasive detection of esophageal cancer can be achieved, and the detection rate of esophageal cancer can be improved.
[0243] In summary, the present application utilizes the above-mentioned composition, nucleic acid sequence, kit and its use, and the above-mentioned detection method, and realizes the in vitro detection of esophageal cancer using target gene target sequence methylation biomarkers by detecting the methylated nucleic acid sequence of the target gene target sequence and its fragments, thereby effectively improving the sensitivity and specificity of in vitro detection of esophageal cancer. By using the method of analyzing free DNA of plasma samples by real-time PCR, it is possible to conveniently detect the methylation state of the target gene target sequence, and it is possible to quickly and conveniently determine whether the sample is positive based on the CT value of the real-time PCR, providing a non-invasive and convenient in vitro detection method for esophageal cancer.
[0244] Although various aspects and embodiments of the present invention are disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for illustrative purposes only and not for limiting purposes. The scope and spirit of the present invention are determined solely by the appended claims. Sequence Listing <110> Boercheng (Beijing) Technology Co., Ltd. <120> Composition for detecting esophageal cancer and use thereof <130> PA00035D1 <160> 12 <170> PatentIn version 3.5 <210> 1 <211> 171 <212> DNA <213> Human <400> 1 cacccagggg agctcagtgg actgtgcgcc ttgcctttct gctgcgcaaa gcccagtcca 60 ggtcatcacc tcgggcgggg cggactcggc tgggcggact cagcggggcg ggcgcaggcg 120 cagggcgggt cctttgcgtc cggccctctt tcccctgacc ataaaagcag c 171 <210> 2 <211> 171 <212> DNA <213> Human <400> 2 gctgctttta tggtcagggg aaagagggcc ggacgcaaag gacccgccct gcgcctgcgc 60 ccgccccgct gagtccgccc agccgagtcc gccccgcccg aggtgatgac ctggactggg 120 ctttgcgcag cagaaaggca aggcgcacag tccactgagc tcccctgggt g 171 <210> 3 <211> 259 <212> DNA <213> Human <400> 3 cgcgcacgca cacatgcaga taacagcccc gacccccggc cagagccgca gagtccctgg 60 gccaccccgg ccgctcgctg cgctgcgccg caccgcgctg tcctcccgga gccggaccgg 120 ggccaccgcg cccgctctgc tccgacaccg cgccccctgg acagccgccc tctcctccag 180 gcccgtgggg ctggccctgc accgccgagc ttcccgggat gagggccccc ggtgtggtca 240 cccggcgcgc cccaggtcg 259 <210> 4 <211> 259 <212> DNA <213> Human <400> 4 cgacctgggg cgcgccgggt gaccacaccg ggggccctca tcccgggaag ctcggcggtg 60 cagggccagc cccacgggcc tggaggagag ggcggctgtc cagggggcgc ggtgtcggag 120 cagagcgggc gcggtggccc cggtccggct ccgggaggac agcgcggtgc ggcgcagcgc 180 agcgagcggc cggggtggcc cagggactct gcggctctgg ccgggggtcg gggctgttat 240 ctgcatgtgt gcgtgcgcg 259 <210> 5 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 5 cggacgtaaa ggattc 16 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 6 gaaacgaact cgactaaacg 20 <210> 7 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Probe <400> 7 tgcgtttgcg ttcgtttcg 19 <210> 8 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Blockers <400> 8 caaactcaac taaacaaact caacaaaaca aac 33 <210> 9 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 9 agtcgtagag tttttgggtt 20 <210> 10 <211> 15 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 10 caacgcgata cgacg 15 <210> 11 <211> 16 <212> DNA <213> Artificial sequence <220> <223> Probe <400> 11 cgcaacgaac gaccga 16 <210> 12 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Blockers <400> 12 gagtttttgg gttattttgg ttgtttgttg 30
Claims
1. Use of a composition in preparing a kit for in vitro detection of esophageal cancer, the composition comprising: Nucleic acid used to detect the methylation status of the target gene, Wherein, the target genes are MT1A gene and EPO gene, Wherein, the target sequence of the MT1A gene is shown in SEQ ID NO: 1, and The target sequence of the EPO gene is shown in SEQ ID NO:
3.
2. The use according to claim 1, wherein The nucleic acid used to detect the methylation status of the target gene includes: A fragment of at least 9 nucleotides in the target sequence of the target gene, The fragment comprises at least one CpG dinucleotide sequence.
3. The use according to any one of claims 1 to 2, wherein The nucleic acid used to detect the methylation status of the target gene includes: A fragment of at least 15 nucleotides that hybridizes to the target sequence of the target gene under moderately stringent or stringent conditions, The fragment comprises at least one CpG dinucleotide sequence.
4. The use according to claim 3, further comprising: A reagent that converts unmethylated cytosine base at position 5 of the target gene sequence into uracil.
5. The use according to claim 1, wherein The nucleic acid for detecting the methylation status of the target gene also includes: Blockers that preferentially bind to target sequences in their unmethylated state.
6. Use of the target sequence of MT1A gene and the target sequence of EPO gene in preparing a kit for in vitro detection of esophageal cancer, in, The target sequence of the MT1A gene is shown in SEQ ID NO: 1, and The target sequence of the EPO gene is shown in SEQ ID NO:
3.
7. The use according to claim 6, wherein The kit for in vitro detection of esophageal cancer detects esophageal cancer by a method comprising the following steps: Separating a DNA sample including a target gene target sequence or a fragment thereof from a biological sample to be tested; Determining the methylation status of the target gene target sequence; and The state of the biological sample is judged by the detection result of the methylation state of the target gene target sequence, thereby realizing in vitro detection of esophageal cancer.
8. The use according to claim 7, wherein The method comprises the following steps: Extracting genomic DNA from the biological sample to be tested; Treat the extracted genomic DNA with a reagent to convert the unmethylated cytosine base at position 5 into uracil or other bases; contacting the reagent-treated DNA sample with a DNA polymerase and a primer of a target sequence of a target gene, and performing a DNA polymerization reaction in the presence of a blocking agent that preferentially binds to the target sequence in a non-methylated state; Detect the amplified product using a probe; as well as Based on the presence or absence of the amplification product, the methylation status of at least one CpG dinucleotide of the target sequence of the target gene is determined.
9. The use according to claim 8, wherein The reagent is a bisulfite reagent.
